N530-ADC

N530-ADC is an experimental antibody-drug conjugate (ADC) currently in the preclinical stage of development by Nanolattix. Distinguishing itself from traditional ADCs that utilize full-length monoclonal antibodies, N530-ADC employs a nanobody—a small, single-domain antibody fragment—as its targeting mechanism. This nanobody-based approach is intended to improve the drug's ability to penetrate tumor tissues and bind to specific antigens with high affinity. N530-ADC is being developed for the treatment of various solid tumors, specifically lung cancer, cervical cancer, and ovarian cancer. As of the current pipeline status, the specific molecular target and the cytotoxic payload associated with N530-ADC have not been disclosed.